Kanyos Bio is looking for volunteers with celiac disease to participate in the ACeD Study (Assessment of KAN-101 in Celiac Disease), a phase 1 clinical trial testing the investigational drug KAN-101.
KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.
- 18-70 years old
- Biopsy-confirmed celiac disease
- On a gluten-free diet for at least the last 12 months